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Abstract
Background: Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors
(TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and
the optimal EGFR TKI to be used remains unclear. This study aims to assess the real-life diagnostic and clinical
management and outcome of patients with advanced non-small-cell lung cancer (NSCLC) carrying EGFR mutations
in Spain.
Methods: All consecutive patients recently diagnosed with advanced or metastatic NSCLC from April 2010 to
December 2011 in 18 Spanish hospitals and carrying EGFR mutations were retrospectively evaluated.
Results: Between March and November 2013, a total of 187 patients were enrolled (98.3% Caucasian, 61.9% female,
54.9% never-smokers, 89.0% adenocarcinoma). Mutation testing was mainly performed on biopsy tumour tissue
specimens (69.0%) using a qPCR-based test (90%) (47.0% Therascreen EGFR PCR Kit). Common sensitising mutations
were detected in 79.8% of patients: 57.1% had exon 19 deletions and 22.6% exon 21 L858R point mutations. The
vast majority of patients received first-line therapy (n = 168; 92.8%). EGFR TKIs were the most commonly used first-
line treatment (81.5%), while chemotherapy was more frequently administered as a second- and third-line option
(51.9% and 56.0%, respectively). Of 141 patients who experienced disease progression, 79 (56.0%) received second-
line treatment. After disease progression on first-line TKIs (n = 112), 33.9% received chemotherapy, 8.9%
chemotherapy and a TKI, and 9.8% continued TKI therapy. Most patients received first-line gefitinib (83.0%), while
erlotinib was more frequently used in the second-line setting (83.0%). Progression-free survival (PFS) and overall
survival (OS) in patients harbouring common mutations were 11.1 months and 20.1 months respectively (exon 19
deletions: 12.4 and 21.4 months; L858R: 8.3 and 14.5 months), and 3.9 months and 11.1 months respectively for
those with rare mutations.
Conclusion: EGFR TKIs (gefitinib and erlotinib) are used as the preferred first-line treatment while chemotherapy is
more frequently administered as a second- and third-line option in routine clinical practice in Spain. In addition,
efficacy data obtained in the real-life setting seem to concur with data from EGFR TKI phase III pivotal studies in
NSCLC.
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Background
Non-small-cell lung cancer (NSCLC) accounts for more
than 85% of lung cancer cases [1] with the majority of
patients presenting with advanced disease at the time of
diagnosis [2]. Standard first-line treatment for advanced
disease has usually consisted of conventional cytotoxic
chemotherapy, mostly platinum-based regimens, al-
though it provides limited benefits with regard to sur-
vival [3, 4]. Advances in targeted and individualised
treatment have led to the development of anti-epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs), such as first-generation TKIs (gefitinib, erlotinib)
and second-line TKIs (afatinib), which irreversibly bind
to the tyrosine kinase receptor. In addition, said ad-
vances have brought about the recently-available third-
generation TKIs such as osimertinib, an oral, irreversible
EGFR-TKI that is selective for both EGFR and T790 M
resistance mutations and acts on the central nervous
system. The development of these treatment strategies
has markedly improved both clinical management and
the outcome of patients with advanced NSCLC.
These targeted agents have shown a higher efficacy
among patients harbouring specific activating mutations
in exons 18–21 encoding the tyrosine kinase domain of
the EGFR gene [5–10]. The most common EGFR activat-
ing mutations are exon 19 deletions (45%) and the L858R
exon 21 point mutation (40–45%) [11, 12]. East Asians, fe-
males, never-smokers and patients with adenocarcinoma
histology, who are associated with a higher incidence of
EGFR activating mutations [13], have been shown to de-
rive a greater clinical benefit from EGFR TKIs [5, 14, 15].
A large body of randomised clinical trials demon-
strated the superior clinical effectiveness of EGFR TKIs
compared with standard chemotherapy in patients with
stage IIIB or IV NSCLC whose tumours tested positive
for EGFR mutations [7–10, 13, 16, 17]. A large propor-
tion of studies with these targeted agents were carried
out in Asian patients from Japan, China and South
Korea, where the incidence of EGFR mutations was high.
However, some studies demonstrating the clinical benefit
of TKIs over chemotherapy have been conducted in
Caucasian populations (EURTAC [7], IFUM [18]), there-
fore confirming that the presence of EGFR mutations
and not ethnicity is the most reliable factor predicting
sensitivity to EGFR TKIs. All studies reported a superior
benefit in overall response rate (ORR) and improvement
[7–10, 13, 16, 17] in progression-free survival (PFS) for
patients with EGFR mutation-positive NSCLC treated
with TKIs compared with standard chemotherapy. None
of the individual studies found a significant difference in
overall survival (OS) between TKIs and chemotherapy,
probably due to subsequent treatments and the high de-
gree of crossover that may have confounded the effect of
the initial first-line treatment.
The enhanced response to EGFR TKIs in patients har-
bouring activating mutations led to the recommendation
of upfront EGFR mutation testing to guide therapeutic
decision-making [19–22]. However, there is no consen-
sus on the optimal detection method to identify EGFR
mutations [23, 24] and the sources of tumour material
(biopsy tumour tissue samples, cytology specimens or
serum samples) have been a notable consideration in
EGFR mutation detection.
Although the benefit of EGFR TKIs over chemother-
apy has been clearly demonstrated in the first-line set-
ting in several clinical trials, data from clinical practice is
lacking and there are still some concerns regarding the
optimal EGFR TKI to be used. Moreover, the most bene-
ficial therapy (EGFR TKIs or chemotherapy) and the role
of EGFR mutation status in second-line treatment and
beyond still remain the subject of debate.
In addition to the lack of data available from routine
clinical practice in patients with EGFR-mutated NSCLC,
particularly in Caucasians, there is an unmet need for
real-life data on treatment patterns and outcome at a na-
tional level in Spain. This study was conducted to assess
the clinical management and outcome of patients with
advanced NSCLC carrying EGFR-positive mutations in
the real-world clinical setting in Spain.
Methods
Study design and patients
This was a multicentre, retrospective, observational study
conducted in 18 hospitals throughout Spain. All adult pa-
tients (aged ≥18 years) recently diagnosed with histologi-
cally or cytologically confirmed advanced NSCLC from
April 2010 to December 2011 and carrying EGFR-positive
mutations were retrospectively evaluated.
The study was carried out in accordance with the Dec-
laration of Helsinki and applicable regulatory require-
ments. Approval of the study protocol was obtained
from the Hospital del Mar Clinical Research Ethics
Committee (Barcelona, Spain). Written informed con-
sent was obtained from all patients to retrospectively
collect data from medical charts.
The primary endpoint of the study was to describe
the diagnostic and clinical management patterns of pa-
tients with advanced or metastatic NSCLC carrying
EGFR-positive mutations. For this purpose, EGFR mu-
tation testing methods, source of tumour material,
treatment setting and therapeutic strategies were ana-
lysed. Secondary endpoints included the clinical out-
come (ORR, PFS and OS) of the overall population
according to the line of therapy and treatment received
(chemotherapy or EGFR TKIs [gefitinib or erlotinib]),
the type of EGFR mutation (common or rare sensitising
mutations, exon 19 deletion or L858R point mutation),
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and other relevant clinical characteristics (i.e. Eastern Co-
operative Oncology Group [ECOG] performance status).
Statistical analysis
A descriptive analysis was performed of diagnostic and clin-
ical management variables collected from patient medical
records. Quantitative variables were described using mea-
sures of central tendency and dispersion (mean, median,
standard deviation [SD], minimum, maximum, first quartile
and third quartile) and the results are expressed as mean ±
SD or median (range). Qualitative variables are presented
as absolute and relative frequencies. Efficacy analyses were
conducted on the patients who had available data from at
least one evaluation of response (8 weeks for EGFR TKI
and 6 weeks for chemotherapy). Tumour response was
assessed based on the unidimensional Response Evaluation
Criteria In Solid Tumors (RECIST) version 1.1 [25] if the
disease was measurable or by the investigator in those pa-
tients with a non-measurable disease according to local
practice. ORR was calculated as the sum of patients achiev-
ing complete response and partial response as the best re-
sponse achieved. PFS was assessed from the start of therapy
for NSCLC until documented disease progression or death
from any cause. Patients were censored at the date of last
follow-up if still alive or without disease progression at the
time of the analysis. OS was calculated as the time elapsed
from the start of treatment to death. Patients were censored
at the date of last follow-up if still alive at the time of the
analysis. The probability of PFS and OS was estimated
using the Kaplan-Meier method.
The statistical analysis was performed using the statis-
tical package SAS version 9.02.
Results
Patient population
A total of 187 newly diagnosed advanced NSCLC patients
(from April 2010 to December 2011) from 18 Spanish
sites were retrospectively evaluated between March and
November 2013. Six patients were excluded as they did
not meet the inclusion criteria (the informed consent of
two patients was not available and four patients were not
diagnosed between April 2010 and December 2011). The
demographic and clinical characteristics of the 181 evalu-
able patients are shown in Table 1. Briefly, 61.9% were
female, 98.3% were Caucasian and 54.9% were never-
smokers. The most frequent comorbidities were hyperten-
sion (48.1%), dyslipidaemia (21.0%), diabetes (14.4%),
cardiovascular disease (11.6%), and chronic obstructive
pulmonary disease (COPD) (10.5%). The most common
histological type was adenocarcinoma (89.0%). ECOG per-
formance status at diagnosis of advanced disease was 0 or
1 in 80.1% of patients. Most patients (87.8%) had stage IV
disease at diagnosis. Metastases were mainly located in
the lungs (45.7%), bone (42.9%) and pleura (28.6%).
EGFR mutation analysis
Mutation testing was mainly conducted in external la-
boratories (68.0%). The median time elapsed from the
date the sample was sent to the laboratory until the re-
sults were obtained (turnaround time [TAT]) was 8.5
Table 1 Patients´ demographic and clinical characteristics
Characteristic Value (n = 181)







Smoking history, n (%)
Former smoker 53 (30.3)
Current smoker 26 (14.9)
Never smoker 96 (54.9)





Tumor histology, n (%)
Adenocarcinoma 161 (89.0)
Squamous cell carcinoma 9 (5.0)
Large cell carcinoma 5 (2.8)
Adenosquamous cell carcinoma 2 (1.1)
Carcinoma NOS 4 (2.2)





Median number of metastatic sites (range) 2.0 (1.0–3.0)




Lymph nodes 45 (25.7)
Pleural effusion 30 (17.1)
CNS 25 (14.3)
Liver 25 (14.3)
CNS Central nervous system, ECOG PS Eastern Cooperative Oncology Group
Performance Status, NOS Not otherwise specified
aOther clinical stages included: IA (one patient), IIA (5 patients) and IIB (one
patient), bMetastatic locations presented in > 10% of patients
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[7.0–12.0] days and 13.0 [5.0–20.0] days in external and
internal laboratories, respectively. EGFR mutation test-
ing was mainly performed using quantitative polymer-
ase chain reaction (qPCR)-based tests (90.0%). The
Therascreen® EGFR RGQ PCR kit (QUIAGEN) was the
most frequently used method for mutation testing
(47.0%). EGFR mutation analysis was performed on bi-
opsy tumour samples in 123 (68.7%) patients and on
cytology specimens in 55 (30.7%) patients. Tumour
tissue was primarily obtained from the primary tumour
(72.9%). Tissue samples were mainly obtained through
bronchoscopy (42.5%) or fine-needle aspiration (32.2%).
The EGFR mutation testing methods and the source
and type of tumour samples for mutation testing are
shown in Table 2.
Among patients with available EGFR mutation type in-
formation (n = 168), sensitising mutations were detected
in 157 (93.5%) patients. Of these, 134 (85.4%) patients
harboured common sensitising mutations: 96 (61.1%)
had exon 19 deletions and 38 (24.2%) exon 21 L858R
point mutation. Other EGFR sensitising mutations found
less frequently are described in Table 3.
Treatment
The vast majority of the patients had received first-line
treatment after diagnosis of advanced NSCLC (92.8%).
TKIs were used as first-line treatment in the majority of
patients (81.5%), while chemotherapy-based regimens
were more commonly administered as second- and
third-line options (51.9% and 56.0%, respectively). First-
line chemotherapy followed by maintenance EGFR TKIs
was used in less than 5% of patients. Of the 168 patients
who received first-line treatment, 79 (47.0%) underwent
second-line treatment and 25 (14.9%) and 10 (6.0%) re-
ceived third- and fourth-line treatment, respectively
(Table 4).
Of 141 patients who experienced disease progression
on first-line treatment, 79 (56.0%) patients received
second-line treatment. After disease progression on first-
line EGFR TKIs (n = 112), 33.9% received chemotherapy,
8.9% chemotherapy and TKI, and 9.8% received further
treatment with single agent TKI therapy. The majority
of patients received first-line gefitinib treatment (83.2%),
while erlotinib was the most frequent TKI used in the
second-line setting (83.3%).
Of patients who received first-line chemotherapy
(18.5%), doublet chemotherapy was used in 77.4% and
60.5% of patients as first and second-line treatment op-
tion, respectively.
In addition to pharmacological treatments, 36 (19.9%)
patients underwent surgery (mainly palliative procedures
involving minor surgery), and 71 (39.2%) received pallia-
tive radiotherapy.
Efficacy
A total of 150/168 (89.3%) and 64/79 (81.0%) patients
harbouring EGFR mutations were evaluable for efficacy
analyses in first- and second-line setting, respectively.
At database lock, 120 (66.3%) patients had died, 29
(16.0%) patients were alive and had not experienced dis-
ease progression, 22 (12.2%) patients showed disease
progression, and 10 (5.5%) patients were lost-to-follow-
up. The median follow-up was 13.3 (0.4–38) months.
Clinical outcomes for patients according to treatment for
advanced NSCLC
The ORR was 46.8% for patients treated with an EGFR
TKI (gefitinib: 50.0%; erlotinib: 36.4%) and 22.2% for
those receiving chemotherapy. Clinical efficacy in terms
Table 2 Methods, source and type of tumor samples for EGFR
mutation testing
Methods for EGFR mutation testing (n = 181) n (%)
Therascreen EGFR Mutation Test kit (ARMS) (Qiagen) 85 (47.0)
RT-PCR (not specified) 26 (14.4)
Fluorescent PCR fragment length analysis 22 (12.2)
Direct sequencing 20 (11.0)
Cobas EGFR Mutation Test kit (Roche) 9 (5.0)
Allelic discrimination using fluorogenic probes 4 (2.2)
Digital PCR 2 (1.1)
Double PCR 1 (0.6)
Non specified 16 (8.8)
Sample characteristics n (%)
Biopsy (n = 121) 123 (68.7)
Tumor tissue source
Primary tumor 94 (77.7)
Metastatic sites 27 (22.3)
Cytology (n = 55) 55 (30.7)
Tumor tissue source
Primary tumor 35 (63.6)
Metastatic sites 20 (36.4)









Data not available 2 (1.1)
EBUS Endobronchial ultrasound, FNA Fine-needle aspiration
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of response is detailed in Table 5. PFS was 9.9 (95% confi-
dence interval [CI]: 8.3–11.5) months with first-line EGFR
TKIs (gefitinib: 9.9 [95% CI: 8.3–11.7] months, erlotinib: 9.9
[95% CI: 4.8–15.0] months), 5.2 (95% CI: 3.8–7.1) months
with standard chemotherapy and 7.6 (95% CI: 6.1–17.4)
with chemotherapy followed by maintenance TKI therapy.
Median OS was 16.7 (95% CI: 12.4–20.1) months and 23.7
(95% CI: 15.2–31.5) months with first-line gefitinib and er-
lotinib, respectively, 12.7 (95% CI: 9.3–21.0) months with
chemotherapy and 16.6 (95% CI: 10.6–26.7) months for
chemotherapy and maintenance TKIs (Table 5).
Clinical outcomes for patients according to ECOG
performance status
EGFR TKI treatment was more frequently used as first-
line treatment in patients with poor ECOG PS (2 or 3)
(100% in patients with PS 2 or 3 and 79% in those with
PS 0 or 1). ORR was 46.8% (Disease control rate [DCR]:
87.2%) in patients with ECOG 0–1 and 47.6% (DCR:
95.2%) in those with ECOG 2–3. PFS was 9.9 (95% CI:
7.9–11.7) months for patients with ECOG 0 or 1 and
11.2 (95% CI: 9.5–19.7) months for those with worse
ECOG. Finally, OS and one-year survival were 17.4 (95%
CI: 13.4–25.5) months and 62.5% respectively in patients
with ECOG 0–1 and 16.8 (95% CI: 10.7-not calculated)
months and 54.9% in those with ECOG 2–3.
Clinical outcomes for patients according to EGFR mutation
type
Of the 132 patients with EGFR sensitising mutations
evaluable for efficacy, 112 (84.8%) had common sensi-
tising mutations (exon 19 mutations and exon 21
L858R mutations) and 20 (15.2%) rare mutations (exon
18 G719X, G719A, G719S mutations and exon 21
L861Q mutation). Ninety-six (85.7%) and 16 (80.0%)
patients with common and rare sensitising mutations
received first-line TKIs, gefitinib being the most fre-
quently used TKI in patients with common (81.3%) and
rare (93.8%) mutations. Rare sensitising mutations
present in tumours of patients treated with first-line
TKIs were exon 18 G719A (2 [12.5%]), exon 18 G719S
(2 [12.5%]), exon 18 G719X (7 [43.8%]) and exon 21
L861Q (5 [31.3%]) mutations.
ORR was 53.1% in patients with common mutations
(exon 19 deletions: 54.4%; L858R point mutations:
50.0%) and 12.5% in those carrying rare mutations
(Table 6). PFS and OS in patients harbouring common
mutations were 11.1 months and 20.1 months respect-
ively, and 3.9 months and 11.1 months for those with
rare mutations (Fig. 1a and b). PFS and OS in patients
with exon 19 deletions was 12.4 (95% CI: 10.5–16.2) and
21.4 (95% CI: 17.4-not calculated) months, and 8.3 (95%
CI: 4.7–11.1) and 14.5 (95% CI: 10.4–31.5) months re-
spectively for those harbouring L858R (Fig. 1c and d).
EGFR TKI treatment resulted in an ORR of 53.1% in
patients with common sensitising EGFR mutations who
received TKIs while the ORR for those receiving
chemotherapy was 18.8% (Table 6). The median PFS in
patients carrying common sensitising mutations and
treated with first-line TKIs was 11.1 (95% CI: 9.3–12.7)
months while those receiving chemotherapy showed a
PFS of 5.8 (95% CI: 4.2–7.6) months. The median OS
was 20.1 (95% CI: 15.7–31.5) months with first-line
EGFR TKIs and 12.1 (95% CI: 9.4-not achieved) months
with chemotherapy.
Table 3 Common and rare sensitizing and not sensitizing
mutations
Mutations (n = 168)a n (%)
Sensitizing mutations 157 (93.4)
Common 134 (79.8)
Exon 19 (all mutations) 96 (57.1)
Exon 21 L858R 38 (22.6)
Rare 23 (13.7)
Exon 18 G719X 10 (5.6)
Exon 18 G719A 3 (1.8)
Exon 18 G719S 3 (1.8)
Exon 21 L861Q 7 (4.2)
Not sensitizing mutations 7 (4.2)
Exon 20 (all mutations) 7 (4.2)
Mutations of unknown significance 4 (2.4)
Exon 21 L858Q 1 (0.6)
Exon 21 E829Q 1 (0.6)
Exon 21 R836C 1 (0.6)
Exon 21 T854S 1 (0.6)
aMutation type not available for 1 patient with exon 18 and 11 patients with
exon 11 mutations
Table 4 Treatment characteristics by line of treatment
Treatment First-line Second-line Third-line Fourth-line
n (%) n (%) n (%) n (%)
N 168 79 25 10
TKI 137 (81.5) 24 (30.4) 6 (24.0) 5 (50.0)
Gefitinib 114 (83.2) 4 (16.7) 1 (16.7) 0 (0.0)
Erlotinib 23 (16.8) 20 (83.3) 4 (66.7) 0 (0.0)
Afatinib 0 (0.0) 0 (0.0) 1 (16.7) 5 (100)
CT 31 (18.5) 43 (54.4) 14 (56.0) 4 (40.0)
Doublet 24 (77.4) 26 (60.5) 5 (35.7) 1 (25.0)
Monochemotherapy 4 (12.9) 16 (37.2) 8 (57.1) 2 (50.0)
Triplet 3 (9.7) 1 (2.3) 1 (7.1) 1 (25.0)
CT + maintenance TKI 8 (4.8) 1 (1.3) 0 (0.0) 0 (0.0)
CT + maintenance CT 2 (1.2) 1 (1.3) 0 (0.0) 0 (0.0)
Other 0 (0.0) 1 (1.3) 2 (8.0) 0 (0.0)
CT Chemotherapy, TKI Tyrosine kinase inhibitor
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Discussion
The present study examined the patterns of diagnostic
and clinical management of patients with NSCLC carry-
ing EGFR-positive mutations in routine clinical practice
in Spain. As expected for patients carrying EGFR muta-
tions and in line with previous reports in Caucasians
[18], we found a population with a high proportion of fe-
males, never-smoker patients, and adenocarcinoma hist-
ology. Additionally, consistent with previous data in
Caucasian patients, the majority of EGFR activating
mutations were exon 19 deletions (57.1%) and exon 21
L858R point mutations (22.6%) [12].
As seen in our study, a variety of methodologies are
used for EGFR mutation detection, as there is currently
no consensus on the optimal method or source used for
testing. The heterogeneity in the detection method has a
potential relevance due to the differences in sensitivity
between methods. Direct sequencing of DNA has trad-
itionally been the “gold standard” for EGFR mutation
testing, though this method is mainly limited by its
Table 5 Summary of efficacy by first-line treatment (TKI or chemotherapy) and TKI type (gefitinib or erlotinib) in the evaluable
population
Endpoint First-line treatment TKI subtype
TKI CT CT + TKI maintenance Gefitinib Erlotinib
Evaluable 124 18 8 100 22
Response, n (%)
CR 3 (2.2) 2 (11.1) 0 (0.0) 2 (2.0) 1 (4.5)
PR 55 (44.4) 2 (11.1) 2 (25.9) 48 (48.0) 7 (31.8)
SD 51 (41.1) 10 (55.6) 6 (75.0) 36 (36.0) 13 (59.1)
PD 15 (12.1) 4 (22.2) 0 (0.0) 14 (14.0) 1 (4.5)
ORR, n (%) 58 (46.8) 4 (22.2) 2 (25.0) 50 (50.0) 8 (36.4)
95% CI 37.8–55.9 6.4–47.6 3.2–65.1 39.8–60.2 17.2–59.3
DCR, n (%) 109 (87.9) 14 (77.8) 8 (100) 86 (86.0) 21 (95.5)
95% CI 80.8–93.1 52.4–93.6 63.1–100.0 77.6–92.1 77.2–99.9
Median PFS (95% CI), months 9.9 (8.3–11.5) 5.2 (3.8–7.1) 7.6 (6.1–17.4) 9.9 (8.3–11.7) 9.9 (4.8–15.0)
One-year PFS, n (%) 37.3 0.0 12.5 36.6 34.1
Median OS (95% CI), months 17.2 (13.5–21.4) 12.7 (9.3–21.0) 16.6 (10.6–26.7) 16.7 (12.4–20.1) 23.7 (15.2–31.5)
One-year OS, n (%) 61.7 50 37.5 59.8 66.6
CI: Confidence interval; CR: Complete response; DCR: Disease control rate; ORR: Overall response rate; OS: Overall survival; PR: Partial response; PD: Progressive
disease; PFS: Progression-free survival; SD: Stable disease
Table 6 Summary of efficacy according to EGFR sensitizing mutation (common or rare) and common sensitizing EGFR mutation
type (exon 19 deletion or L858R) and first-line treatment (EGFR TKI or chemotherapy) used in patients carrying common sensitizing
EGFR mutations
EGFR sensitizing mutation (n = 132) mutation (n = 131) Common sensitizing EGFR mutation (n = 112)
Type of mutation First-line treatment
Endpoint Common Rare Del 19 L858R TKI CT
Evaluable 112 20 82 30 96 16
Response, n (%)
CR 3 (3.1) 0 (0.0) 2 (2.9) 1 (3.6) 3 (3.1) 1 (6.3)
PR 48 (50.0) 2 (12.5) 35 (51.5) 13 (46.4) 48 (50.0) 2 (12.5)
SD 38 (39.6) 8 (50.0) 27 (39.7) 11 (39.3) 38 (39.6) 11 (68.8)
PD 7 (7.3) 6 (37.5) 4 (5.9) 3 (10.7) 7 (7.3) 2 (12.5)
ORR, n (%) 51 (53.1) 2 (12.5) 37 (54.4) 14 (50.0) 51 (53.1) 3 (18.8)
95% CI 42.7–63.4 1.6–38.4 41.9–66.5 30.6–69.4 42.7–63.4 4.0–45.6
DCR, n (%) 89 (92.7) 10 (62.5) 64 (94.1) 25 (89.3) 89 (92.7) 14 (87.5)
95% CI 85.6–97.0 35.4–84.8 85.6–98.4 71.8–97.7 85.6–97.0 61.7–98.4
CI Confidence interval, CR Complete response, DCR Disease control rate, ORR Overall response rate, PR Partial response, PD Progressive disease, SD Stable disease
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moderate sensitivity and a long TAT [26, 27]. Indeed,
only a small proportion of tumour samples (11.0%) were
analysed using direct sequencing in daily-care patients
analysed. EGFR mutation testing was primarily performed
using RT-PCR-based tests (80.0%), the Therascreen® EGFR
Mutation Test kit (ARMS) being the most commonly ap-
plied mutation testing assay, which has demonstrated im-
proved sensitivity and TAT [28]. Paraffin-embedded
tumour tissue specimens have conventionally been the
main source of tumour material for EGFR mutation test-
ing in lung cancer and they currently still account for the
majority of diagnostic samples in the clinical practice. Cy-
tology specimens have been proven to be an adequate al-
ternative source for mutation testing when tissue samples
are not available or have a low content of tumour DNA
[29, 30] and their use has increased over recent years. In
our study, tumour tissue from bronchial biopsy was the
most frequently used source of tumour material for EGFR
mutation analysis (70.0%) while cytology specimens were
used in about one third of patients at the time when the
study was carried out.
The median TAT of 9 days seen in our study for sam-
ple analysis performed externally demonstrates a well-
structured set up for this analysis in Spain. This allows
physicians to have information available for treatment
decision-making within an adequate time period after
diagnosis, even in centres without local facilities to per-
form the analysis.
With regard to clinical management, one of the main
findings of our study is the high proportion of patients
who received EGFR TKIs in the first-line setting (82.0%),
even though some of the current targeted agents were not
available for patients harbouring EGFR mutations (e.g. er-
lotinib and afatinib) or had recently been approved at the
time when the patients were diagnosed (e.g., gefitinib was
marketed in March 2010). As expected, the most fre-
quently used first-line TKI was gefitinib (83.2%). There-
fore, EGFR TKI treatment may have been introduced
early in the therapeutic armamentarium for advanced
NSCLC in Spain. These findings therefore suggest that
EGFR mutation testing may have been adopted early as a
routine procedure to guide therapeutic decision-making
in clinical practice in Spain even before it was widely
adopted and recommended by major oncology groups, in-
cluding the Spanish Society of Medical Oncology (SEOM)
and the Spanish Society of Pathology (SEAP) [19–21, 31].
a b
c d
Fig. 1 Kaplan-Meier curves for progression-free survival (a) and overall survival (b) for EGFR TKI-treated patients carrying common and rare EGFR sensi-
tising mutations and Kaplan-Meier curves for progression-free survival (c) and overall survival (d) for patients treated with an EGFR TKI harbouring exon
19 deletions or L858R point mutations. CI: Confidence interval; NE: Not evaluable; OS: Overall survival; PFS: Progression-free survival
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While TKIs were used as first-line treatment in the
majority of patients, chemotherapy-based regimens were
the preferred second-line option in our series. Only a
small proportion of patients continued EGFR TKI ther-
apy after disease progression, with a similar number of
patients receiving single-agent TKI and TKIs plus
chemotherapy. Acquired resistance to EGFR TKIs is the
main limitation to a long-lasting benefit of these targeted
agents in patients with EGFR mutation-positive NSCLC
[32], with the EGFR T790 M mutation being responsible
for resistance in up to 60% of cases [33]. However, with-
drawal of an EGFR TKI at the onset of resistance may
lead to rapid tumour growth [34, 35]. The potential
benefit of continuing EGFR TKI treatment beyond dis-
ease progression has been addressed in several studies in
the last years [36–38]. The single-arm phase II study
ASPIRATION supports the feasibility of continuation
of single-agent erlotinib beyond disease progression in
patients with EGFR mutation-positive NSCLC [37].
However, further research based on randomised stud-
ies is needed before firm conclusions can be drawn.
The phase III IMPRESS study showed that continu-
ation of gefitinib in combination with platinum-based
doublet chemotherapy after disease progression on
first-line gefitinib did not prolong PFS compared with
chemotherapy alone in patients with NSCLC carrying
EGFR mutations [38]. The third-generation EGFR in-
hibitors, which can selectively target both sensitising
mutations and the T790 M mutation, have demon-
strated the benefit of continuing EGFR TKI treatment
beyond progression for patients with T790 M
mutation-positive NSCLC [39]. The recent approval
of the third-generation EGFR TKI osimertinib may
change the treatment paradigm after disease progres-
sion on EGFR TKI treatment in patients with
T790 M mutation-positive NSCLC for which no other
resistance mechanisms are identified.
Regarding the efficacy data, we found that tumour
response and survival seem to be similar between ge-
fitinib and erlotinib in real-life patients. However, the
differences in the proportion of patients receiving
first-line gefitinib and erlotinib in our series and the
lack of matched comparisons make it difficult to ob-
tain reliable data from our descriptive analysis. As a
descriptive comparison only, considering the obvious
limitations, the PFS achieved in this study with gefi-
tinib (9.9 months) was within the range reported in
the clinical trials carried out with gefitinib in Asian
patients with advanced NSCLC [16, 40, 41] and the
PFS data reported with gefitinib in a European popu-
lation of Caucasian patients with advanced NSCLC
harbouring EGFR mutations [18]. Similarly, erlotinib
resulted in a comparable PFS to that reported in clin-
ical trials with this targeted agent in Caucasians [7].
As expected, efficacy figures seem to be superior for
patients harbouring common sensitising mutations in re-
lation to those with rare mutations. Of note, only 12.5%
of the patients carrying rare sensitising mutations
(G719X) responded to EGFR-TKIs. Such a low response
rate raises the question of whether these mutations
should be considered “sensitizing” at all when it comes
to EGFR first-generation TKIs.
Furthermore, PFS and OS appear to be longer for EGFR
TKI-treated patients carrying exon 19 deletions compared
with those with L858R point mutations. These findings are
in line with previous clinical trials where numerical but
non-significant differences in PFS were shown between pa-
tients treated with gefitinib harbouring exon 19 deletions
and those with the L858R point mutation (11.5 months vs.
10.8 months, p = 0.90 in the NEJ002; Hazard ratio [HR] =
1.13, 95% CI = 0.63–2.03, p = 0.68 in the WJTOG3405) [5,
7, 16]. Similarly, a beneficial effect in favour of patients re-
ceiving the recently introduced TKI afatinib and carrying
the exon 19 deletions was reported [8, 9].
In addition to the obvious limitations, arising from the
retrospective nature of the study, the authors acknow-
ledge that one of the main limitations of this study is the
incorporation of the second-generation EGFR TKI afati-
nib for EGFR-mutated NSCLC in the last years which
may have changed the prescription patterns regarding
the type of EGFR TKI used. Despite these limitations,
our findings still offer a valid global picture regarding
the management of EGFR-mutant NSCLC patients who
typically receive EGFR TKIs as their initial therapy. In
addition, this study might offer a welcome addition to
the limited “real-world” data on treatment patterns and
clinical outcome of patients carrying EGFR-positive mu-
tations in clinical practice, particularly in Caucasians.
Our national data collection therefore provides an inter-
esting overview of real-life clinical practice for the man-
agement of EGFR-mutated NSCLC in Spain.
Conclusions
To our knowledge, this is the first study to have focused
on the clinical management and outcome of real-life pa-
tients with advanced EGFR-mutated NSCLC in Spain.
Our data show that EGFR TKIs were used as the pre-
ferred first-line treatment while chemotherapy was more
frequently administered as a second- and third-line op-
tion. In addition, efficacy data, in terms of PFS and OS,
obtained from our national real-world data collection,
seem consistent with data from EGFR TKI phase III piv-
otal studies in NSCLC.
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